BackgroundThe use of temozolomide (TMZ) has improved the prognosis for glioblastoma multiforme patients. However, TMZ resistance may be one of the main reasons why treatment fails. Although this resistance has frequently been linked to the expression of O6-methylguanine-DNA methyltransferase (MGMT) it seems that this enzyme is not the only molecular mechanism that may account for the appearance of drug resistance in glioblastoma multiforme patients as the mismatch repair (MMR) complex, P-glycoprotein, and/or the presence of cancer stem cells may also be implicated.MethodsFour nervous system tumor cell lines were used to analyze the modulation of MGMT expression and MGMT promoter methylation by TMZ treatment. Furthermore, 5-aza-2’-deoxycytidine was used to demethylate the MGMT promoter and O(6)-benzylguanine to block GMT activity. In addition, MMR complex and P-glycoprotein expression were studied before and after TMZ exposure and correlated with MGMT expression. Finally, the effect of TMZ exposure on CD133 expression was analyzed.ResultsOur results showed two clearly differentiated groups of tumor cells characterized by low (A172 and LN229) and high (SF268 and SK-N-SH) basal MGMT expression. Interestingly, cell lines with no MGMT expression and low TMZ IC50 showed a high MMR complex expression, whereas cell lines with high MGMT expression and high TMZ IC50 did not express the MMR complex. In addition, modulation of MGMT expression in A172 and LN229 cell lines was accompanied by a significant increase in the TMZ IC50, whereas no differences were observed in SF268 and SK-N-SH cell lines. In contrast, P-glycoprotein and CD133 was found to be unrelated to TMZ resistance in these cell lines.ConclusionsThese results may be relevant in understanding the phenomenon of TMZ resistance, especially in glioblastoma multiforme patients laking MGMT expression, and may also aid in the design of new therapeutic strategies to improve the efficacy of TMZ in glioblastoma multiforme patients.

Doxorubicin, one of the most effective anticancer drugs currently known, is commonly used against breast cancer. However, its clinical use is restricted by dose-dependent toxicity (myelosuppression and cardiotoxicity), the emergence of multidrug resistance and its low specificity against cancer cells. Nanotechnology is a promising alternative to overcome these limitations in cancer therapy as it has been shown to reduce the systemic side-effects and increase the therapeutic effectiveness of drugs. Indeed, the numerous nanoparticle-based therapeutic systems developed in recent years have shown low toxicity, sustained drug release, molecular targeting, and additional therapeutic and imaging functions. Furthermore, the wide range of nanoparticle systems available may provide a solution to the different problems encountered during doxorubicin-based breast cancer treatment. Thus, a suitable nanoparticle system may transport active drugs to cancer cells using the pathophysiology of tumours, especially their enhanced permeability and retention effects, and the tumour microenvironment. In addition, active targeting strategies may allow doxorubicin to reach cancer cells using ligands or antibodies against selected tumour targets. Similarly, doxorubicin resistance may be overcome, or at least reduced, using nanoparticles that are not recognized by P-glycoprotein, one of the main mediators of multidrug resistance, thereby resulting in an increased intracellular concentration of drugs. This paper provides an overview of doxorubicin nanoplatform-based delivery systems and the principal advances obtained in breast cancer chemotherapy.

: Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6- guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy as part of the first-line treatment of high-grade gliomas. The main advantages are its high oral bioavailability (almost 100% although the concentration found in the cerebrospinal fluid was approximately 20% of the plasma concentration of TMZ), its lipophilic properties, and small size that confer the ability to cross the blood-brain barrier. Furthermore, this agent has demonstrated activity not only in brain tumors but also in a variety of solid tumors. However, conventional therapy using surgery, radiation, and TMZ in glioblastoma results in a median patient survival of 14.6 months. Treatment failure has been associated with the tumor drug resistance. This phenomenon has been linked to the expression of O6-methylguanine-DNA methyltransferase, but the mismatch repair system and the presence of cancer stem-like cells in tumors have also been related to TMZ resistance. The understanding of these mechanisms is essential for the development of new therapeutic strategies in the clinical use of TMZ, including the use of nanomaterial delivery systems and the association with other chemotherapy agents. The aim of this review is to summarize the resistance mechanisms of TMZ and the current advances to improve its clinical use.

Abstract:Here we describe a new theropod, Bicentenaria argentina nov. gen. et nov. sp., from the early Late Cretaceous of Patagonia. It is represented by more than a hundred bones belonging to different sized individuals, which were buried together in disarticulation after little transportation. The available association of skeletal elements suggests a gregarious behaviour for Bicentenaria, an ethological trait also recorded among other theropod clades. Increasing documentation of monospecific assemblages of different groups of theropods suggests that a gregarious behaviour may have constituted the ancestral condition for Theropoda, at least. Bicentenaria characterizes for the surangular bone with a high dorsal margin and a prominent lateral shelf, a retroarticular process that is low, wide and spoon-shaped, and quadrate bone with its lateral condyle larger than the medial one. Phylogenetic analysis found the Chinese Tugulusaurus and the Patagonian Bicentenaria as successive sister taxa of all other coelurosaurs, thus revealing the importance of the new taxon in the understanding of the early diversification of Coelurosauria. In particular, Bicentenaria amplifies the array of basal coelurosaurs that inhabited Gondwana during the Cretaceous, also including compsognathids, Aniksosaurus and Santanaraptor. Although still restricted to a handful of forms, available information indicates that Gondwana was a cradle for the evolution of different lineages of basal coelurosaurs, different from those documented in Upper Cretaceous beds in the northern landmasses. Analysis of body size distribution in averostran theropods results in the identification of two main episodes of drastic size reduction in the evolutionary history of Coelurosauria: one occurred at the initial radiation of the group (as represented by Bicentenaria, Zuolong, Tugulusaurus, compsognathids, and Aniksosaurus), and a second episode occurred at the early diverification of Paraves or avialans. Reduction in body size may have allowed adult coelurosaurians to exploit ecological niches not occupied before by larger basal averostrans.Key words: Coelurosauria, gregarism, body size reduction, Cretaceous, South America.Resumen: Nuevo terópodo del Cretácico de Patagonia brinda nuevas evidencias acerca de la radiación temprana de Coelurosauria. En la presente contribución se describe el nuevo terópodo Bicentenaria argentina nov. gen. et nov. sp., del Cretácico Tardío temprano de Patagonia. El nuevo taxón se encuentra representado por más de una centena de huesos pertenecientes a individuos de diferentes tamaños, los cuales fueron enterrados todos juntos en desarticulación, luego de un leve transporte. La asociación disponible de materiales sugiere hábitos gregarios para Bicentenaria, un rasgo etológico también registrado en otros clados de terópodos. La documentación recurrente de asociaciones monoespecíficas de diferentes grupos de terópodos sugiere que los hábitos gregarios pudieron haber constituido la condición ancestral para Theropoda. Bicentenaria se caract...

BackgroundThe CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O6-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen and promoter methylation and protein expression of MGMT in a homogenous group of GBM patients uniformly treated with radiotherapy and TMZ. The possible connection between these GBM markers was also investigated.MethodsSeventy-eight patients with GBM treated with radiotherapy combined with concomitant and adjuvant TMZ were analyzed for MGMT and CD133. MGMT gene promoter methylation was determined by methylation-specific polymerase chain reaction after bisulfite treatment. MGMT and CD133 expression was assessed immunohistochemically using an automatic quantification system. Overall and progression-free survival was calculated according to the Kaplan–Meier method.ResultsThe MGMT gene promoter was found to be methylated in 34 patients (44.7%) and unmethylated in 42 patients (55.3%). A significant correlation was observed between MGMT promoter methylation and patients’ survival. Among the unmethylated tumors, 52.4% showed low expression of MGMT and 47.6% showed high-expression. Among methylated tumors, 58.8% showed low-expression of MGMT and 41.2% showed high-expression. No correlation was found between MGMT promoter methylation and MGMT expression, or MGMT expression and survival. In contrast with recent results, CD133 expression was not a predictive marker in GBM patients. Analyses of possible correlation between CD133 expression and MGMT protein expression or MGMT promoter methylation were negative.ConclusionsOur results support the hypothesis that MGMT promoter methylation status but not MGMT expression may be a predictive biomarker in the treatment of patients with GBM. In addition, CD133 should not be used for prognostic evaluation of these patients. Future studies will be necessary to determine its clinical utility.